Antiarrhythmic Effect of Statin Therapy and Atrial Fibrillation. A Meta-Analysis of Randomized Controlled Trials

Journal of the American College of Cardiology

Volumn 51, Issue 8, 2008, Pages 828-835

  Fauchier, Laurent ^a   Pierre, Bertrand ^a   de Labriolle, Axel ^a   Grimard, Caroline ^a   Zannad, Noura ^a   Babuty, Dominique ^a  

^a SERVICE DE DERMATOLOGIE   (France)

Author keywords

[No Author keywords available]

Indexed keywords

ATORVASTATIN; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; PLACEBO; PRAVASTATIN; ROSUVASTATIN;

ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; DRUG EFFECT; HEART ATRIUM FIBRILLATION; HUMAN; INCIDENCE; META ANALYSIS; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; RECURRENT DISEASE; SYSTEMATIC REVIEW;

ATRIAL FIBRILLATION; HUMANS; HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITORS; INCIDENCE; RANDOMIZED CONTROLLED TRIALS AS TOPIC; RECURRENCE;

EID: 39149142513     PISSN: 07351097     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.jacc.2007.09.063     Document Type: Article

References (29)

1. Fuster V., Ryden L.E., Cannom D.S., et al. ACC/AHA/ESC 2006 guidelines for the management of patients with atrial fibrillation-executive summary: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines and the European Society of Cardiology Committee for Practice Guidelines (Writing Committee to Revise the 2001 Guidelines for the Management of Patients With Atrial Fibrillation). J Am Coll Cardiol 48 (2006) 854-906
2. Kostapanos M.S., Liberopoulos E.N., Goudevenos J.A., Mikhailidis D.P., and Elisaf M.S. Do statins have an antiarrhythmic activity?. Cardiovasc Res 75 (2007) 10-20
3. Tveit A., Grundtvig M., Gundersen T., et al. Analysis of pravastatin to prevent recurrence of atrial fibrillation after electrical cardioversion. Am J Cardiol 93 (2004) 780-782
4. Schwartz G.G., Olsson A.G., Chaitman B., Goldberger J., Szarek M., and Sasiela W.J. Effect of intensive statin treatment on the occurrence of atrial fibrillation after acute coronary syndrome: an analysis of the MIRACL trial. Circulation 110 Suppl (2004) S740
5. Chello M., Patti G., Candura D., et al. Effects of atorvastatin on systemic inflammatory response after coronary bypass surgery. Crit Care Med 34 (2006) 660-667
6. Ozaydin M., Varol E., Aslan S.M., et al. Effect of atorvastatin on the recurrence rates of atrial fibrillation after electrical cardioversion. Am J Cardiol 97 (2006) 1490-1493
7. Patti G., Chello M., Candura D., et al. Randomized trial of atorvastatin for reduction of postoperative atrial fibrillation in patients undergoing cardiac surgery. Results of the ARMYDA-3 (Atorvastatin for Reduction of MYocardial Dysrhythmia After cardiac surgery) Study. Circulation 114 (2006) 1455-1461
8. Dernellis J., and Panaretou M. Effect of C-reactive protein reduction on paroxysmal atrial fibrillation. Am Heart J 150 (2005) 1064
9. Schwartz G.G., Olsson A.G., Ezekowitz M.D., et al. Myocardial Ischemia Reduction with Aggressive Cholesterol Lowering (MIRACL) Study Investigators. Effects of atorvastatin on early recurrent ischemic events in acute coronary syndromes: the MIRACL study: a randomized controlled trial. JAMA 285 (2001) 1711-1718
10. Kinlay S., Schwartz G.G., Olsson A.G., et al. High-dose atorvastatin enhances the decline in inflammatory markers in patients with acute coronary syndromes in the MIRACL study. Circulation 108 (2003) 1560-1566
11. Jadad A.R., Moore R.A., Carroll D., et al. Assessing the quality of reports of randomized clinical trials: is blinding necessary?. Control Clin Trials 17 (1996) 1-12
12. Moher D., Cook D.J., Eastwood S., et al. Improving the quality of reports of meta-analyses of randomized controlled trials: the QUOROM statement. Lancet 354 (1999) 1896-1900
13. Fleiss J.L. Statistical Methods for Rates and Proportions. 2nd edition (1981), John Wiley & Sons, New York, NY
14. Mantel N., and Haenszel W. Statistical aspects of the analysis of data from retrospective studies of disease. J Natl Cancer Inst 22 (1959) 719-748
15. DerSimonian R., and Laird N. Meta-analysis in clinical trials. Control Clin Trials 7 (1986) 177-188
16. Mathew J.P., Fontes M.L., Tudor I.C., et al. A multicenter risk index for atrial fibrillation after cardiac surgery. JAMA 291 (2004) 1720-1729
17. Engelmann M.D.M., and Svedsen J.H. Inflammation in the genesis and perpetuation of atrial fibrillation. Eur Heart J 26 (2005) 2083-2092
18. Liu T., Li G., Li L., and Korantzopoulos P. Association between C-reactive protein and recurrence of atrial fibrillation after successful electrical cardioversion: a meta-analysis. J Am Coll Cardiol 49 (2007) 1642-1648
19. Strandberg T.E., VanhanenH, and Tikkanen M.J. Effect of statins on C-reactive protein in patients with coronary artery disease. Lancet 353 (1999) 118-119
20. Plenge J.K., Hernandez T.L., Weil K.M., et al. Simvastatin lowers C-reactive protein within 14 days: an effect independent of low-density lipoprotein cholesterol reduction. Circulation 106 (2002) 1447-1452
21. Botto G.L., Luzi M., and Sagone A. Atrial fibrillation: the remodeling phenomenon. Eur Heart J 5S Suppl (2003) H1-H7
22. Healey J.S., Baranchuk A., Crystal E., et al. Prevention of atrial fibrillation with angiotensin-converting enzyme inhibitors and angiotensin receptor blockers: a meta-analysis. J Am Coll Cardiol 45 (2005) 1832-1839
23. Lozano H.F., Conde C.A., Florin T., and Lamas G.A. Treatment and prevention of atrial fibrillation with nonantiarrhythmic pharmacologic therapy. Heart Rhythm 2 (2005) 1000-1007
24. Rosenson R.S. Statins in atherosclerosis: lipid-lowering agents with antioxidant capabilities. Atherosclerosis 173 (2004) 1-12
25. Liu T., and Li G.P. Statins may prevent postoperative atrial fibrillation through autonomic modulation. Am J Cardiol 97 (2006) 1266
26. Antman E.M., Lau J., Kupelnick B., Mosteller F., and Chalmers T.C. A comparison of results of meta-analyses of randomized control trials and recommendations of clinical experts. Treatments for myocardial infarction. JAMA 268 (1992) 240-248
27. Lau J., Antman E.M., Jimenez-Silva J., Kupelnick B., Mosteller F., and Chalmers T.C. Cumulative meta-analysis of therapeutic trials for myocardial infarction. N Engl J Med 327 (1992) 248-254
28. Kjekshus J., Dunselman P., Blideskog M., et al. A statin in the treatment of heart failure? Controlled Rosuvastatin Multinational Study in Heart Failure (CORONA): study design and baseline characteristics. Eur J Heart Fail 7 (2005) 1059-1069
29. Baigent C., Keech A., Kearney P.M., et al., Cholesterol Treatment Trialists' Collaborators. Efficacy and safety of cholesterol-lowering treatment: prospective meta-analysis of data from 90,056 participants in 14 randomised trials of statins. Lancet 366 (2005) 1267-1278